UroNav System Combines MRI and Ultrasound for Prostate Biopsies

UroNav System Combines MRI and Ultrasound for Prostate Biopsies
Every year, approximately 239,000 men are diagnosed with prostate cancer, but while most will die with the cancer and not from it, some men will have the type of prostate cancer that aggressively and rapidly kills. The new focus of today's oncological research is to accurately identify and differentiate a slow-growing cancer from a life-threatening one, and give a diagnosis as early as possible. A team of cancer experts from the University of Michigan Comprehensive Cancer Center are advancing this diagnostic approach, using the UroNav System, which combines magnetic resonance imaging (MRI) with ultrasound technology. Associate Professor of urology and chief of urologic oncology at the cancer center, Ganesh Palapattu, M.D., compares the standard approach to obtain prostate biopsies to shooting fish in a barrel with your eyes blindfolded because of its random nature. He adds that using the UroNav system is like taking the blindfold off and sampling areas most likely to reveal an aggressive cancer. This makes the center the first in the region to offer this new, more precise biopsy technique that ensures samples from all suspicious areas are obtained. The UroNav System allows urologists to determine the exact positions of suspicious lesions, resulting in a more purposeful navigation of the biopsy needle. The system can also store the needles' trajectories in its memory, allowing a repetition of the biopsies in the same targeted areas. Cancer specialists at the university have been using a similar biopsy system for research purposes over the past 2 years. UroNav can be highly beneficial in the following: Patients with concerning prostate MRI results Patients considering or currently under close observation for prostate cancer Patients f
Subscribe or to access all post and page content.